Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06708455Phase 2Not Yet Recruiting

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Role: lead

NCT06169176Unknown

RAPA-501 Therapy of ALS Expanded Access Protocol

Role: lead

NCT04220190Phase 2Recruiting

RAPA-501 Therapy for ALS

Role: lead

NCT04176380Phase 2Completed

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Role: lead

NCT05144698Phase 1Recruiting

RAPA-201 Therapy of Solid Tumors

Role: lead

NCT04482699Phase 1Terminated

RAPA-501-Allo Therapy of COVID-19-ARDS

Role: lead

All 6 trials loaded